Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models
- 28 February 1995
- journal article
- Published by Elsevier BV in Bone
- Vol. 16 (2), 235-245
- https://doi.org/10.1016/8756-3282(94)00035-x
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Transient recruitment of osteoclasts and expression of their function in osteopetrotic (op/op) mice by a single injection of macrophage colony-stimulating factorJournal of Bone and Mineral Research, 1993
- Effects of 4-amino-1-hydroxybutylidene bisphosphonate on bone biomechanics in ratsJournal of Bone and Mineral Research, 1992
- The bisphosphonate, alendronate, prevents bone loss in ovariectomized baboonsJournal of Bone and Mineral Research, 1992
- Effects of amino-butylidene diphosphonate in hypercalcemia due to malignancyBone, 1991
- BisphosphonatesDrugs, 1991
- Role of bone and kidney in parathyroid hormone-related peptide-induced hypercalcemia in ratsJournal of Bone and Mineral Research, 1989
- Role of glucocorticoids in management of malignant hypercalcaemia.BMJ, 1984
- The Hypercalcemia of CancerNew England Journal of Medicine, 1984
- Treatment of hypercalcaemia associated with malignancy.BMJ, 1984
- Parathyroid Hormone Effects in Rats Treated with DiphosphonateScience, 1974